2024 Perth Nurse Melanoma Symposium

Join us for an engaging educational day designed for all nurses who care for melanoma patients. 

Hosted by Melanoma Institute Australia, in collaboration with the WA Kirkbride Melanoma Advisory Service and Cancer Network Western Australia, our one-day symposium will give you practical insights from multidisciplinary experts and provide an opportunity to network with fellow nurses.

The 2024 Perth Nurse Melanoma Symposium program covers the whole spectrum of the disease including the use of AI in melanoma, medical advancements and the management of systemic therapy side effects. 

Program:

• Melanoma awareness and prevention - Dr Chris Quirk (Dermatologist)
• Use of AI in melanoma - Dr Tony Caccetta (Dermatologist)
• Understanding pathology in melanoma - Prof Benjamin Wood (Pathologist)
• Rare forms of melanoma and non-melanoma skin cancer - Julie Teraci (CNC Skin Cancer & Melanoma)
• Which patients are seen at WAKMAS? - Stacey Coke (CNC)
• Support for melanoma patients - Angie Miller (Melanoma Community Support Nurse)
• Medical management of melanoma - Dr Tom van Hagen (Medical Oncologist)
• Systemic therapy side effects - Caitlin Broderick (Nurse Practitioner)

(Please note this Program is subject to change)

Refreshments will be provided.

Date: Thursday 25th July 2024. Registration opens at 8.30am with the event commencing at 9am.

Venue: Harry Perkins Institute of Medical Research, 6 Verdun St, Nedlands WA 6009

Cost: $55 (inc GST)

CPD: A certificate of attendance will be given to attendees

RSVP: By 18th July 2024

Safety at our event: Please follow COVID-safe practices when attending our event and stay home if you are feeling unwell. If you can no longer attend due to COVID-19, please contact us.

This educational event is an initiative of Melanoma Institute Australia in collaboration with WA Kirkbride Melanoma Advisory Service and Cancer Network Western Australia.

MIA’s Education Program is proudly supported through unrestricted educational grants from: MSD, Bristol Myers Squibb and HEINE.